Pazopanib adjuvant trial rcc

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free. Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.

The following article features coverage from the American Society of Clinical Oncology meeting. Continue Reading. Please login or register first to view this content. More, pazopanib as adjuvant treatment did not improve disease-free survival in this group of patients, further confirming the existing literature regarding patients with localized or locally advanced RCC.

Motzer, MD. Pazopanib is not recommended as adjuvant therapy following resection of locally advanced RCC. When analyzing OS, the research team found no significant differences between the adjuvant pazopanib arm and the placebo arm HR, 1. Motzer reported. In secondary analyses, pazopanib did have a significant disease-free survival benefit among patients started on the mg dose hazard ratio, 0.

One possible explanation for the differing results seen with the two doses was the difference in follow-up, as the mg group was treated earlier in the trial, he proposed. But with an additional year of blinded follow-up, the benefit in the mg group actually diminished, whereas that in the mg group did not. Motzer noted.

Overall survival was statistically indistinguishable between the pazopanib and placebo groups, regardless of dose. A quality of life analysis for the mg group using the item Functional Assessment of Cancer Therapy FACT Kidney Symptom Index FKSI showed values were consistently lower with the drug than with placebo during treatment, with a crossing of the threshold for a minimally important difference at week 8.

Pharmacokinetic analyses from the trial, reported in a poster at the meeting Abstract , showed that in the group starting pazopanib at mg, disease-free survival was longer in patients who achieved higher drug trough concentrations at week 3 or 5. Skip to main content.